Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Avant

Nurse Practitioner, Family Leawood, KS Nurse Practitioner

NPI 1568831584 CMS profile 10683660

11550 Granada St Ste 200, Leawood, KS 66211

Open in the dashboard

General payments

$10,212

458 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Avant of Leawood, KS is reported in the CMS Open Payments database as having received $10,212 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,416 117
2024 General $3,708 147
2023 General $2,012 88
2022 General $1,185 50
2021 General $891 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Avant
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Amy Avant were reported at $2,416. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Amy Avant Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $891 $124 $35–$379 $132
2022 $1,185 $141 $44–$430 $149
2023 $2,012 $154 $49–$476 $160
2024 $3,708 $165 $51–$504 $164
2025 $2,416 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,542 93 payments
  2. E.R. Squibb & Sons, L.L.C. $1,227 68 payments
  3. LEO Pharma Inc. $1,071 21 payments
  4. Janssen Biotech, Inc. $882 31 payments
  5. Amgen Inc. $659 30 payments
  6. Novartis Pharmaceuticals Corporation $474 23 payments
  7. UCB, Inc. $436 21 payments
  8. Sun Pharmaceutical Industries Inc. $408 17 payments
  9. Genzyme Corporation $396 12 payments
  10. Dermavant Sciences, Inc. $368 26 payments
  11. Other $2,748 116 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,928 448 payments
  2. Consulting Fee $700 1 payment
  3. Education $584 9 payments
Products named General payments · program years 2021–2025
  1. SOTYKTU $1,124 65 payments
  2. TREMFYA $917 33 payments
  3. Otezla $659 30 payments
  4. RINVOQ $502 23 payments
  5. DUPIXENT $500 12 payments
  6. SKYRIZI $440 34 payments
  7. Bimzelx $436 21 payments
  8. HUMIRA $400 24 payments
  9. VTAMA $396 29 payments
  10. OPZELURA $342 16 payments
  11. Other $3,608 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

484

Median for Nurse Practitioner: 389

Drug cost

$8,776

Median for Nurse Practitioner: $21,885

Branded share of claims

4.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 74 $2,305
Ketoconazole Generic 86 $1,518
Metronidazole Generic 18 $960
Triamcinolone Acetonide Generic 80 $907
Fluorouracil Generic 11 $760
Doxycycline Hyclate Generic 35 $736
Mupirocin Generic 67 $466
Valacyclovir Valacyclovir Hcl Brand 20 $305
Finasteride Generic 13 $184
Nystatin Generic 11 $172

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$111,016

Of which drugs: $20,576

Medicare patients

466

Average age 74

Services billed

2,867

305 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 45%
Ischemic heart disease 21%
Diabetes 19%
Osteoporosis 19%
Depression 18%
Cancer 17%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 32 68 $20,564

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $351
$351 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $349
$349 — —
TREMFYA
  • Janssen Biotech, Inc. $217
  • Janssen Pharmaceuticals, Inc $35
$252 — —
SKYRIZI
  • AbbVie, Inc. $212
$212 — —
Otezla
  • Amgen Inc. $192
$192 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record